Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Controlled, Blinded, Pilot Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients

Next Previous
Search
Trial Profile

Randomized, Controlled, Blinded, Pilot Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Food hypersensitivity
  • Focus Therapeutic Use
  • Acronyms MAP-X; MAPX; mOIT MAP-X

    • Most Recent Events

    • 28 Feb 2022 Results evaluating the difference in OIT-related allergic adverse events (AEs) between home versus clinic dose among participants who received omalizumab in randomized phase 2 studies MAPX and MIMIX, presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 28 Feb 2022 Results (n=42) investigating predictors of successful desensitization, presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 30 Mar 2021 Results assessing Immune Changes Beyond Th2 Pathways During Rapid Multifood Immunotherapy enabled with Omalizumab published in the Allergy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top